SG
CRL icon

Societe Generale’s Charles River Laboratories CRL Stock Holding History

Societe Generale’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.3M Buy
+15,795
New +$1.3M 0.01% 1129

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Societe Generale's CRL Position: Q2 2016 in Review

Societe Generale opened a new position in Charles River Laboratories (CRL) in Q2 2016: 15,795 shares worth $1.3M. The stake represents 0.01% of the portfolio and ranks #1129 among its holdings.

286 funds tracked by Wall St. Rank hold CRL as of Q2 2016.

  • Societe Generale held 15,795 shares of Charles River Laboratories worth $1.3M as of Q2 2016.
  • Charles River Laboratories was a new Societe Generale position in Q2 2016.
  • Charles River Laboratories made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1129 holding.
  • 286 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.